Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence

New England Journal of Medicine

Volumn 367, Issue 19, 2012, Pages 1803-1813

  Visco, Anthony G ^a   Brubaker, Linda ^c   Richter, Holly E ^d   Nygaard, Ingrid ^e   Paraiso, Marie Fidela R ^f   Menefee, Shawn A ^g   Schaffer, Joseph ^h   Lowder, Jerry ⁱ   Khandwala, Salil ^j   Sirls, Larry ^k   Spino, Cathie ^l   Nolen, Tracy L ^b   Wallace, Dennis ^b   Meikle, Susan F ^m  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^k OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; SOLIFENACIN; TROSPIUM CHLORIDE;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA;

EID: 84868576429     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1208872     Document Type: Article

References (22)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
2. Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. Evid Rep Technol Assess (Full Rep) 2009;187:1-120.
3. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22.
4. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. Contemp Clin Trials 2012;33:184-96.
5. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71-7. [Erratum, BJU Int 2004;93:1135.]
6. Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007;178:978-83.
7. Brubaker L, Kreder L, Richter HE, et al. Refractory Urge Urinary Incontinence and Botulinum A Injection: the methods of the RUBI Trial. J Appl Res 2006;6:260-71.
8. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25.
9. Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T. The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn 2007;26:196-203.
10. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 2005;193:103-13.
11. Yalcin I, Bump RC. Validation of two Global Impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98-101.
12. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006;176:627-32.
13. Dyer KY, Xu Y, Brubaker L, et al. Minimum important difference for validated instruments in women with urge incontinence. Neurourol Urodyn 2011;30:1319-24.
14. Diokno AC, Sand PK, Macdiarmid S, Shah R, Armstrong RB. Perceptions and behaviours of women with bladder control problems. Fam Pract 2006;23:568-77.
15. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11:Suppl:S121-S129.
16. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505.
17. Herschorn S, Becker D, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol 2004;11:2430-7.
18. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988-93.
19. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003781.
20. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22.
21. Gordon MF, Barron R. Effectiveness of repeated treatment with botulinum toxin type A across different conditions. South Med J 2006;99:853-61.
22. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68:1193-7.